| Biography | |
|---|---|
 Dr. Wu Du Hinova Pharmaceuticals Inc., China |
|
| Title: Towards medicines of new concept: a case study of AR targeting PROTACs for prostate cancer | |
| Abstract: Targeted protein degradation by proteolysis targeting chimera (PROTAC) emerges as a breakthrough in small molecule drug discovery. PROTACs are composed of 3 moieties that allow the molecule to promote ubiquitin transfer to target protein and subsequent degradation of the target protein by proteasome. The relatively high molecular weights of PROTAC molecules make their druggability a particular challenge. This presentation will overview the evolution of early AR targeting PROTACs and present recent advances in discovery of oral AR PROTACs. | |
| Biography: Dr. Wu Du received his Ph.D. in organic chemistry from the University of Pittsburgh. After completing his postdoc at The Scripps Research Institute, he joined Merck Research Laboratory as a medicinal chemist. He later joined PTC Therapeutics, and then Hinova Pharmaceuticals in Chengdu, China, where he currently serves as a senior vice president. Dr. Du has over 20 years of experience on medicinal chemistry, organic synthesis, drug discovery in oncology and metabolic diseases. While at Hinova, Dr. Du is responsible for oral PROTAC drug discovery. | |
